Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 25;12:816231. doi: 10.3389/fimmu.2021.816231

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Lia, Di Vito, Bruno, Tapparo, Brunello, Santoro, Mariotti, Bramanti, Zaghi, Calvi, Comba, Fascì, Giaccone, Camussi, Boyle, Castagna, Evangelista, Mavilio and Bruno

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Impact of acute GvHD onset on the kinetics of EV membrane protein expression. Proportional change of fluorescence levels of CD146, total EV concentration, CD140a⁺ EV concentration and CD31⁺ EV concentration (left side, from top to bottom), CD120a⁺ EV concentration, CD144⁺ EV concentration, CD26⁺ EV concentration, and fluorescence levels of CD30 from precipitated EVs at different time points before and after aGvHD onset and compared to the pre-transplant baseline values. Dashed black line: pre-transplant levels; dashed red line: time of aGvHD onset; circle and star dots represent outliers (>1.5 box length from median) and extreme values (>3 box length from median), respectively. Significant mean differences before the onset (p ≤ 0.05) between patients with aGvHD (red) and without (blue) are indicated.